Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease

References

• Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761–9.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–33; QUIZ 591.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829–38.
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398–405.
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876–85.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Martinsen TC, Herter R, Dybdahl JH, Waldum HL. Bruk av TNF-alpha-antistoff ved inflammatorisk tarmsykdom. Tidsskr Nor Laegeforen 2010;130:273–7.
   PubMedGoogle Scholar
• Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1017–24; QUIZ 976.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232–9.
   PubMed Web of Science ®Google Scholar
• Lonnkvist MH, Befrits R, Lundberg JO, Lundahl J, Fagerberg UL, Hjortswang H, Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5 years. Eur J Gastroenterol Hepatol 2009;21:1168–76.
   PubMed Web of Science ®Google Scholar
• Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009;24:1252–7.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 1997;337:1029–35.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19–31.
   PubMed Web of Science ®Google Scholar
• Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849–53.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009;23:101–12.
   PubMed Web of Science ®Google Scholar
• Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265–7.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36–41; E1.
   PubMed Web of Science ®Google Scholar
• Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042–9.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Sandler RS, Jordan MC, Kupper LL. Development of a Crohn's index for survey research. J Clin Epidemiol 1988;41:451–8.
   PubMed Web of Science ®Google Scholar
• Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757–90.
   PubMed Web of Science ®Google Scholar
• Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009;23:348–52.
   PubMed Web of Science ®Google Scholar
• Ho GT, Mowat A, Potts L, Cahill A, Mowat C, Lees CW, Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004–2008). Aliment Pharmacol Ther 2009;29:527–34.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91–6.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009;15:1308–19.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492–500.
   PubMed Web of Science ®Google Scholar
• Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6:1212–17; QUIZ 1176.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–36.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47–91.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383–95.
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501–8.
   PubMed Web of Science ®Google Scholar
• Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; in press.
   PubMed Web of Science ®Google Scholar
• REMICADE (infliximab) Summary of Product Characteristics (SPC). Malvern, MA: 2012.
   Google Scholar
• Ierardi E, Valle ND, Nacchiero MC, De Francesco V, Stoppino G, Panella C. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig 2006;26:673–6.
   PubMed Web of Science ®Google Scholar
• Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26:578–81.
   PubMed Web of Science ®Google Scholar
• Moum B, Konopski Z, Tufteland KF, Jahnsen J. Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab. Inflamm Bowel Dis 2007;13:1584–6.
   PubMed Web of Science ®Google Scholar
• O'Donnell S, Murphy S, Anwar MM, O'Sullivan M, Breslin N, O'Connor HJ, Safety of infliximab in 10 years of clinical practice. Eur J Gastroenterol Hepatol 2011;23:603–6.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621–30.
   PubMed Web of Science ®Google Scholar